Ganyan1

PreclinicalSmall molecule

BBeijing Tongren Hospital

Ganyan1 is one of 7 small molecule programs targeting Dry Eye. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Dry EyeNot yet recruiting

Dry EyePreclinical

Not yet recruiting

Competition

Competitive Landscape

10 competitors in Dry Eye

#DrugCompanyPhaseTrials

Neoral

Novartis

Phase 3

1 2

HUMULIN R

BBaxter Healthcare Corporation

Approved

1 3

Vevye

Roche

Phase 3

1 4

Accutane

CConrado Roberto Hoffmann Filho

Preclinical

1 5

Diquafosol Tetrasodium

Merck & Co.

Preclinical

1 6

SYSTANE ULTRA Lubricant Eye

AAlcon Research

Preclinical

1 7

Ganyan1

BBeijing Tongren Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

N/ANot yet recruiting

Dry Eye

NCT06818487

Clinical

Trials by Indication[1]

Dry Eye1 trial

Ganyan-1 in Dry Eye

Not yet recruiting·—·N/A·NCT06818487·219 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ganyan1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ganyan1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ganyan1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Tongren Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BBeijing Tongren Hospital

Ganyan1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Dry Eye1 trial

References

Drug Info

Quick Facts

Related News